Navigation Links
STAAR Surgical Enters Into Distribution Agreement With Ellex in Australia
Date:3/9/2011

MONROVIA, Calif., March 9, 2011 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it has entered into an agreement with Ellex Australia (ASX: ELX) for the exclusive distribution of STAAR intraocular lenses in Australia.  Ellex, a leading ophthalmic manufacturer and distributor that is publicly traded in Australia, will market STAAR's Visian ICL line of refractive lenses, STAAR's intraocular lenses for cataract patients and related products.  STAAR has previously distributed its products in the region through ConceptVision Australia, a wholly owned subsidiary, which is being closed.  During 2010 STAAR generated $1.7 million in sales from the region through a direct team of five employees and generated about $200,000 in net income.  

"We are very pleased to be partnering with Ellex and to have our products join the Ellex portfolio.  We expect its expertise and reputation to improve our market reach in Australia and New Zealand," said Don Todd, STAAR's President of the Asia Pacific Region. "The Ellex organization will start highlighting STAAR products at the Asia Pacific Academy of Ophthalmology (APAO) meeting in Sydney starting on March 21."

"We believe with Ellex's presence in the region, we should be able to drive additional sales and higher profits from this territory over time," said Deborah Andrews, STAAR's Chief Financial Officer.  "As part of the distribution agreement, Ellex will also be purchasing during the first quarter the current inventory of product in Australia for approximately $400,000."

"Ellex is prepared to build on the foundation established by our General Manager at ConceptVision, Phil Stoney, who passed away late last year.  Phil was instrumental to building the STAAR business in the region to its current level, and he was also a loved and respected figure in the Australian ophthalmic community who left us too soon," concluded Mr. Todd.  

About STAAR SurgicalSTAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision.  A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL."  A lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL."  Over 200,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com.  STAAR has approximately 300 full time employees and markets lenses in approximately 50 countries.  Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.  For more information, please visit the Company's website at www.staar.com or call 626-303-7902.  

Safe HarborAll statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: future profits, revenue, sales or any other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; the negative effect of the global recession on sales of products, especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign subsidiaries; the risk of unfavorable changes in currency exchange rates; the broad discretion of regulators in approving medical devices in our major markets; uncertainty as to the effectiveness of newly initiated direct to consumer advertising campaigns, the willingness of surgeons and patients to adopt a new product and procedure; patterns of Visian ICL use that have typically limited our penetration of the refractive surgery market, and a general decline in the demand for refractive surgery, which STAAR believes has resulted both from concerns about the safety and effectiveness of laser procedures and from general economic conditions. CONTACT:

Investors

MediaEVC Group

EVC GroupDouglas Sherk, 415-896-6820

Chris GaleJenifer Kirtland, 415-896-2005

646-201-5431
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
2. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
3. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
4. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
5. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
6. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
7. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
8. 2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
9. Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device
10. Pioneer® Surgical Announces New International Sales V.P.
11. Anesthesiologists Use Caldolor® To Provide Preemptive Pain Control for Surgical Patients at U.S. Medical Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... Montclair, NJ (PRWEB) , ... April 24, 2017 , ... ... International Plaza Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. ... all of our staff hearing this before they approach patients” about the course entitled ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to ... Navigate Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 ... CONTACT USA, and former member of the American Association of Christian Counselors. Rachel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical ... for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed ... product advances towards regulatory and clinical phases. , "This is another important step ...
Breaking Medicine News(10 mins):